Publication | Closed Access

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial

OncologyTumour DnaMedicinePathologyAdvanced Lung AdenocarcinomaBronchial NeoplasmCancer GenomicsCancer TreatmentCancer GeneticsEgfr MutationsMolecular DiagnosticsRadiation OncologyLung Cancer